Postępy Dermatologii i Alergologii

Full text

5/2026 vol. 43
Review paper

Treatment of lichen planopilaris with a focus on emerging therapies

Agnieszka Otlewska-Szpotowicz 1
,
Wojciech Baran 1
,
Aleksandra Batycka-Baran 1

  1. University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, Wroclaw, Poland

Adv Dermatol Allergol 2026; XLIII (5): 457-465

DOI: https://doi.org/10.5114/ada.2026.165951
Data publikacji online: 2026/10/22
Article file
PDiA Treatmet.pdf
  1. Baibergenova A, Donovan J. Lichen planopilaris: update on pathogenesis and treatment. Skinmed 2013; 11: 161-5.
  2. Fechine COC, Valente NYS, Romiti R. Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features. An Bras Dermatol 2022; 97: 348-57.
  3. Rudnicka L, Olszewska M, Rakowska A, et al. Trichoscopy update 2011. J Dermatol Case Rep 2011; 5: 82-85.
  4. Sperling LC, Cowper SE. The histopathology of primary cicatricial alopecia. Semin Cutan Med Surg 2006; 25: 41-50.
  5. Rudnicka L, Kaczorowska A, Waœkiel-Burnat A, et al. Treatment of diseases associated with cicatricial alopecia. Dermatol Rev 2022; 109: 32-42.
  6. Krzes³owska WJ, Woźniacka A. The frontal fibrosing alopecia treatment dilemma. J Clin Med 2024; 13: 2137.
  7. Vanó-Galván S, Saceda-Corralo D, Moreno-Arrones ÓM, et al. Updated diagnostic criteria for frontal fibrosing alopecia. J Am Acad Dermatol 2018; 78: e21-2.
  8. Rácz E, Gho C, Moorman PW, et al. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol 2013; 27: 1461-70.
  9. Beyzaee AM, Goldust M, Patil A, et al. Treatment of frontal fibrosing alopecia. Dermatol Ther 2023; 3: 3856674.
  10. Motamed-Sanaye A, Khazaee JF, Shokrgozar M, et al. JAK inhibitors in lichen planus: a review of pathogenesis and treatments J Dermatol Treat 2022; 33: 3098-103.
  11. Senna MM, Peterson E, Jozic I, et al. Frontiers in lichen planopilaris and frontal fibrosing alopecia research: pathobiology progress and translational horizons. JID Innov 2022; 2: 100-13.
  12. Harries MJ, Meyer K, Chaudhry I, et al. Lichen planopilaris is characterized by immune privilege collapse of the hair follicle’s epithelial stem cell niche J Pathol 2013; 231: 236-47.
  13. Alves de Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One 2016; 11: e0164080.
  14. Chiang C, Sah D, Cho BK, et al. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol 2010; 62: 387-92.
  15. Holmes S, Ryan T, Young D, et al. Frontal Fibrosing Alopecia Severity Index (FFASI): a validated scoring system for assessing frontal fibrosing alopecia. British Hair and Nail Society. Br J Dermatol 2016; 175: 203-7.
  16. Saceda-Corralo D, Moreno-Arrones ÓM, Fonda-Pascual P, et al. Development and validation of the Frontal Fibrosing Alopecia Severity Score. J Am Acad Dermatol 2018; 78: 522-9.
  17. Tan E, Martinka M, Ball N, et al. Primary cicatricial alopecias: clinicopathology of 112 cases. J Am Acad Dermatol 2004; 50: 25-32.
  18. Filbrandt R, Rufaut N, Jones L, et al. Primary cicatricial alopecia: diagnosis and treatment. CMAJ 2013; 185: 1579-85.
  19. Lyakhovitsky A, Amichai B, Sizopoulou C, et al. A case series of 46 patients with lichen planopilaris: demographics, clinical evaluation, and treatment experience. J Dermatol Treat 2015; 26: 275-9.
  20. Sperling LC, Nguyen JV. Commentary: treatment of lichen planopilaris: some progress, but a long way to go. J Am Acad Dermatol 2010; 62: 398-401.
  21. Naeini FF, Saber M, Asilian A, et al. Clinical efficacy and safety of methotrexate versus hydroxychloroquine in preventing lichen planopilaris progress: a randomized clinical trial. Int J Prev Med 2017; 8: 37.
  22. Mostafa N, Phan K, Smith S. Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis. J Dermatol Treat 2022; 33: 369-72.
  23. Azizpour A, Hatami P, Lajevardi V, et al. Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris. Dermatol Ther 2022; 35: e15625.
  24. Naeini FF, Mohaghegh F, Jelvan M, et al. Cyclosporine or methotrexate, which one is more promising in the treatment of lichen planopilaris? A comparative clinical trial. Int Immunopharmacol 2020; 86: 106765.
  25. Babahosseini H, Tavakolpour S, Mahmoudi H, et al. Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. J Dermatol Treat 2019; 30: 598-604.
  26. Vañó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol 2014; 70: 670-8.
  27. Pindado-Ortega C, Saceda-Corralo D, Moreno-Arrones ÓM, et al. Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice. J Am Acad Dermatol 2021; 84: 1285-94.
  28. Vañó-Galván S, Trindade de Carvalho L, Saceda-Corralo D, et al. Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol 2021; 84: 1684-6.
  29. Gupta AK, Talukder M, Shemer A, et al. Low-dose oral minoxidil for alopecia: a comprehensive review. Skin Appendage Disord 2023; 9: 423-37.
  30. Gallo G, Burzi L, Torrelli F, et al. Low-dose oral minoxidil in female patients with lichen planopilaris: real-life experience. J Eur Acad Dermatol Venereol 2023; 37: e98-100.
  31. Pirmez R, Spagnol Abraham L. Eyebrow regrowth in patients with frontal fibrosing alopecia treated with low-dose oral minoxidil. Skin Appendage Disord 2021; 7: 112-4.
  32. Pindado-Ortega C, Pirmez R, Melo DF, et al. Low-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series. Actas Dermosifiliogr 2025; 116: T407-11.
  33. Cranwell WC, Sinclair R. Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation. Australas J Dermatol 2017; 58: e94-6.
  34. Shawky A, Almalki FA, Abdalla AN, et al. A Comprehensive overview of globally approved JAK inhibitors. Pharmaceutics 2022; 14: 1001.
  35. Solimani F, Meier K , Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol 2019; 10: 2847.
  36. Barati Sedeh F, Michaelsdóttir TE, Henning MAS, et al. Comparative efficacy and safety of Janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis. Acta Derm Venereol 2023; 103: adv00855.
  37. Nohria A, Desai D, Shapiro J, et al. Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia. Int J Dermatol 2024; 63: e105-10.
  38. Agarwal P, Ajuchi O, Lukowiak TM, et al. Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review. Arch Dermatol Res 2025; 317: 803.
  39. Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther 2018; 31: e12656.
  40. Plante J, Eason C, Snyder A, et al. Tofacitinib in the treatment of lichen planopilaris: a retrospective review. J Am Acad Dermatol 2020; 83: 1487-9.
  41. Padda IS, Bhatt R, Parmar M. Tofacitinib. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK572148/
  42. Batra P, Sukhdeo K, Shapiro J. hair loss in lichen planopilaris and frontal fibrosing alopecia: not always irreversible. Skin Appendage Disord 2020; 6: 125-9.
  43. Chen LC, Ogbutor C, Kelley KJ, et al. Topical tofacitinib for patients with lichen planopilaris. J Am Acad Dermatol 2024; 90: 1260-2.
  44. Dunn C, Griffith V, Coican A, et al. Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: a case series and review of the literature. JAAD Case Rep 2023; 40: 47-52.
  45. Desai D, Nohria A, Sicco KL, et al. The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: a case report. JAAD Case Rep 2024; 50: 141-3.
  46. Williams KN, Perez SM, Burroway B, et al. Topical ruxolitinib in the management of frontal fibrosing alopecia and/or lichen planopilaris: a single-center retrospective cohort study. J Am Acad Dermatol 2025; 92: 170-2.
  47. Moussa A, Bhoyrul B, Asfour L, et al. Treatment of lichen planopilaris with baricitinib: a retrospective study. J Am Acad Dermatol 2022; 87: 663-6.
  48. Li Z, Yin M, Xu N, et al. Baricitinib as an effective treatment for lichen planopilaris. Dermatol Ther 2022; 35: e15882.
  49. Lasheras-Pérez MA, Palacios-Diaz RD, Pujol-Marco C, et al. Recalcitrant lichen planopilaris treated with upadacitinib: a case series. Int J Dermatol 2024; 63: 1802-4.
  50. David E, Shokrian N, Del Duca E, et al. A phase 2a trial of brepocitinib for cicatricial alopecia. J Am Acad Dermatol 2025; 92: 427-34.
  51. Kasprowicz-Furmañczyk M, Owczarczyk-Saczonek A. The significance of secukinumab in the treatment of plaque psoriasis. Dermatol Rev 2021; 108: 372-84.
  52. Otlewska-Szpotowicz A, Baran W, Woźniak Z, et al. Increased expression of psoriasin (S100A7) and interleukin 17 (IL-17) in lesional skin in lichen planopilaris. Adv Dermatol Allergol 2024; 41: 364-71.
  53. Passeron T, Reinhardt M, Ehst B, et al. Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomised, placebo-controlled, proof-of-concept PRELUDE study. Br J Dermatol 2024; 191: 680-90.
  54. Maurelli M, Colato C, Tessari G, Girolomoni G. Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab. Dermatol Ther 2020; 33: e13967.
  55. Ahmed H, Petkar M, Martin Steinhoff M. Successful treatment of rare linear lichen planopilaris with ixekizumab. J Dermatol Treat 2023; 34: 2201364.
  56. Kreutzer K, Effendy I. Therapy-resistant folliculitis decalvans and lichen planopilaris successfully treated with adalimumab. J Dtsch Dermatol Ges 2014; 12: 74-6.
  57. Alam MS, LaBelle B. Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis. JAAD Case Rep 2020; 6: 219-21.
  58. Buononato D, Argenziano G, Babino G, et al. Effectiveness of adalimumab in lichen sclerosus and lichen planopilaris in a psoriatic patient. Ital J Dermatol Venerol 2023; 158: 154-5.
  59. Jayasekera PS, Walsh ML, Hurrell D, et al. Case report of lichen planopilaris occurring in a pediatric patient receiving a tumor necrosis factor alpha inhibitor and a review of the literature. Pediatr Dermatol 2016; 33: e143-6.
  60. Fernández-Torres R, Paradela S, Valbuena L, et al. Infliximab-induced lichen planopilaris. Ann Pharmacother 2010; 44: 1501-3.
  61. Trindade de Carvalho L, Meah N, Wall D, et al. Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab. Dermatol Ther 2020; 33: e13694.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications